DOXAZOSIN LOWERS BLOOD-PRESSURE AND IMPROVES INSULIN RESPONSES TO A GLUCOSE-LOAD WITH NO CHANGES IN TYROSINE KINASE-ACTIVITY OR INSULIN BINDING

被引：10

作者：

DOMINGUEZ, LJ ^{[1
]}

WEINBERGER, MH ^{[1
]}

CEFALU, WT ^{[1
]}

JACOBS, DB ^{[1
]}

BARBAGALLO, M ^{[1
]}

WALSH, MF ^{[1
]}

SOWERS, JR ^{[1
]}

机构：

[1] WAYNE STATE UNIV,DIV ENDOCRINOL,DETROIT,MI

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 05期

关键词：

DOXAZOSIN; HYPERTENSION; INSULIN; NONINSULIN-DEPENDENT DIABETES MELLITUS; TYROSINE KINASE ACTIVITY; INSULIN BINDING;

D O I：

10.1016/0895-7061(95)00054-S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

alpha-Adrenergic blockers have shown favorable metabolic effects. We evaluated the glucose and insulin responses to a glucose load and lipid profiles in 36 diabetic hypertensive patients before and after 8 weeks of doxazosin administration. To evaluate insulin action at the cellular level, erythrocyte insulin binding and tyrosine kinase (TK) activity were measured in 12 of these patients. Systolic and diastolic blood pressures decreased significantly (P < .0001) after 8 weeks of doxazosin therapy. Doxazosin administration significantly reduced the integrated insulin response (area under the curve [AUC]-insulin: 6093 +/- 894 to 5260 +/- 807; P = .04) and the insulin/glucose index (I/G) at 90 and 120 min after a glucose load (at 90 min, 0.230 +/- 0.055 v 0.180 +/- 0.04, P < .05; at 120 min, 0.275 +/- 0.071 v 0.173 +/- 0.036, P < .05). HDL, level increased from 31.1 +/- 1.5 mg% to 34 +/- 1.6 mg% (P < .05) after doxazosin. Erythrocyte insulin binding and tyrosine kinase activity were not significantly altered after doxazosin. No significant correlation was found between the insulin or glucose responses and the insulin receptor binding or tyrosine kinase activity before and after treatment.

引用

页码：528 / 532

页数：5

共 19 条

[11]

Hupponen, Lehtonen, Vahatalo, Effect of doxazosin on insulin sensitivity in hypertensive-non-insulin dependent diabetic patients, European Journal of Clinical Pharmacology, 43, pp. 365-368, (1992)

[12]

Ferrara, DiMarino, Russo, Et al., Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients, Hypertension, 21, pp. 97-104, (1993)

[13]

Carruthers, Dessain, Podor, Et al., Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group, Am J Cardiol, 71, pp. 575-578, (1993)

[14]

Kahn, White, The insulin receptor and the molecular mechanism of insulin action, J Clin Invest, 82, pp. 1151-1156, (1988)

[15]

Gambhir, Archer, Bradley, Characteristics of human erythrocyte insulin receptors, Diabetes, 27, pp. 701-708, (1978)

[16]

Jacobs, Ireland, Pickett, Et al., Functional characterization of insulin and IGF-I receptors in chicken lens epithelial and fiber cells, Curr Eye Res, 11, pp. 1137-1145, (1992)

[17]

Horton, King, Hirshman, Et al., Failure of insulin to stimulate glucose transporter translocation in skeletal muscle from obese (Ja/Ja) Zucker rat, Diabetes, 39, (1990)

[18]

Resnick, Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders, The American Journal of Medicine, 93, pp. 11S-20S, (1992)

[19]

Maheux, Facchini, Jeppesen, Et al., Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension, Am J Hypertens, 7, pp. 416-424, (1994)

← 1 2 →